Trial · NCT07115641
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 30 of 30
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | The change of TCM syndrome score compared with the baseline and the effective rate | When treating up to the 28th and 84th days | The scale scores corresponding to the primary symptoms are 0, 2, 4, and 6 points respectively, and the scale scores corresponding to the secondary symptoms are 0, 1, 2, and 3 points respectively. A higher score indicates more obvious symptoms. Criteria for Therapeutic Effect of TCM Syndromes: 1. Clinical cure: TCM-related syndromes disappear or basically disappear, and the reduction of syndrome scores is ≥95%; 2. Marked effect: TCM-related syndromes are significantly improved, with a reduction of syndrome scores \>95% and ≥70%; 3. Effective: TCM-related syndromes are improved, with a reduction of syndrome scores \>70% and ≥30%; 4. Ineffective: TCM-related syndromes show no significant improvement or even worsen, with a reduction of syndrome scores \<30%. Total effective rate = \[(Number of cured cases + Number of markedly effective cases + Number of effective cases) / Total number of cases\] × 100% |
| Secondary | The change of the Visual Analogue Scale (VAS) score of the doctor's overall assessment of disease activity (EH) compared with the baseline. | When treating up to the 28th and 84th days | The VAS score ranges from 0 to 100 mm, where 0 represents no pain or no activity, and 100 represents the most severe. |
| Secondary | The change of the Visual Analogue Scale (VAS) score of the subjects' assessment of articular pain (PtAAP) compared with the baseline. | When treating up to the 28th and 84th days | The VAS score ranges from 0 to 100 mm, where 0 represents no pain or no activity, and 100 represents the most severe. |
| Secondary | The change of the Visual Analogue Scale (VAS) score of the subjects' overall assessment of disease activity (GH) compared with the baseline. | When treating up to the 28th and 84th days | The VAS score ranges from 0 to 100 mm, where 0 represents no pain or no activity, and 100 represents the most severe. |
| Secondary | The change of the detected value of C-reactive protein (CRP) compared with the baseline. | When treating up to the 28th and 84th days | |
| Secondary | The change of the detected value of erythrocyte sedimentation rate (ESR) compared with the baseline | When treating up to the 28th and 84th days | |
| Secondary | The change of rheumatoid factor (RF) compared with the baseline | By the 84th day of treatment | |
| Secondary | The change of the inflammatory factor interleukin - 6 (IL - 6) compared with the baseline. | By the 84th day of treatment | |
| Secondary | The changes of coagulation - related indexes compared with the baseline. | By the 84th day of treatment | |
| Secondary | The dosage of Loxoprofen Sodium Tablets | When treating up to the 28th and 84th days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07115641/registered?page=2